Coeptis therapeutics regains compliance with nasdaq minimum bid price requirement for continued listing

Wexford, pa. , sept. 19, 2024 /prnewswire/ -- coeptis therapeutics holdings, inc. (nasdaq: coep) (the "company" or "coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, announced today that it has received a notification letter from the nasdaq hearings panel (the "panel") granting its request for continued listing on the nasdaq stock market ("nasdaq") through january 15, 2025, subject to the company demonstrating compliance with nasdaq listing rule 5550(a)(2).
NDAQ Ratings Summary
NDAQ Quant Ranking